Stephens Investment Management Group LLC Acquires 16,313 Shares of Illumina, Inc. $ILMN

Stephens Investment Management Group LLC boosted its holdings in Illumina, Inc. (NASDAQ:ILMN) by 5.8% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 295,477 shares of the life sciences company’s stock after purchasing an additional 16,313 shares during the period. Stephens Investment Management Group LLC’s holdings in Illumina were worth $28,061,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. WCM Investment Management LLC increased its holdings in shares of Illumina by 5.9% in the second quarter. WCM Investment Management LLC now owns 4,426,471 shares of the life sciences company’s stock worth $419,585,000 after buying an additional 247,460 shares during the period. Loomis Sayles & Co. L P boosted its holdings in Illumina by 1.9% during the 2nd quarter. Loomis Sayles & Co. L P now owns 4,225,529 shares of the life sciences company’s stock valued at $403,158,000 after acquiring an additional 78,317 shares during the period. AQR Capital Management LLC grew its position in Illumina by 55.3% during the 2nd quarter. AQR Capital Management LLC now owns 3,295,880 shares of the life sciences company’s stock worth $313,290,000 after acquiring an additional 1,174,295 shares during the last quarter. Geode Capital Management LLC grew its position in Illumina by 0.7% during the 2nd quarter. Geode Capital Management LLC now owns 2,869,187 shares of the life sciences company’s stock worth $272,921,000 after acquiring an additional 21,342 shares during the last quarter. Finally, Bank of America Corp DE increased its stake in Illumina by 1.9% in the 2nd quarter. Bank of America Corp DE now owns 1,930,843 shares of the life sciences company’s stock worth $184,222,000 after purchasing an additional 35,167 shares during the period. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Stock Down 2.5%

Shares of NASDAQ ILMN opened at $141.65 on Friday. The firm has a fifty day simple moving average of $132.43 and a two-hundred day simple moving average of $111.50. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $151.34. The company has a current ratio of 1.43, a quick ratio of 1.12 and a debt-to-equity ratio of 0.42. The firm has a market capitalization of $21.64 billion, a PE ratio of 31.76, a price-to-earnings-growth ratio of 2.36 and a beta of 1.41.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.16 by $0.18. Illumina had a net margin of 16.40% and a return on equity of 29.21%. The company had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter in the previous year, the company earned $1.14 earnings per share. Illumina’s quarterly revenue was up .4% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. Equities analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on ILMN shares. Robert W. Baird set a $109.00 target price on shares of Illumina in a report on Friday, October 31st. Cowen reissued a “hold” rating on shares of Illumina in a research report on Wednesday, January 7th. Wall Street Zen raised shares of Illumina from a “hold” rating to a “buy” rating in a report on Saturday. Evercore ISI reaffirmed an “outperform” rating and set a $155.00 price objective on shares of Illumina in a research note on Monday, January 5th. Finally, Canaccord Genuity Group increased their target price on shares of Illumina from $112.00 to $130.00 and gave the stock a “hold” rating in a report on Monday, December 22nd. Five analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Illumina presently has a consensus rating of “Hold” and a consensus price target of $122.56.

Insider Activity at Illumina

In other news, Director Scott Gottlieb bought 500 shares of the firm’s stock in a transaction dated Monday, November 3rd. The stock was purchased at an average price of $122.13 per share, with a total value of $61,065.00. Following the transaction, the director owned 12,523 shares of the company’s stock, valued at approximately $1,529,433.99. The trade was a 4.16% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Scott M. Davies sold 323 shares of Illumina stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $136.09, for a total value of $43,957.07. Following the sale, the insider owned 17,887 shares in the company, valued at $2,434,241.83. This represents a 1.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 2.60% of the stock is currently owned by corporate insiders.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.